Lipocine Inc. (LPCN) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 27.40
30Y Low27.4·High27.4
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.94
↓-41% vs avg
5yr avg: 1.61
30Y Low0.7·High5.1
ROE
↓
-54.3%
↑-92% vs avg
5yr avg: -28.2%
30Y Low-194%·High0%
Debt/EBITDA
N/A
—
5yr avg: 0.73
30Y Low0.7·High0.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LPCN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lipocine Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $13M | $46M | $26M | $15M | $36M | $87M | $76M | $10M | $28M | $69M | $67M |
| Enterprise Value | $8M | $41M | $20M | $10M | $32M | $86M | $62M | $7M | $30M | $66M | $62M |
| P/E Ratio → | -1.41 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.58 | 23.19 | 2.36 | — | 71.17 | 5.38 | — | 60.44 | 64.85 | — | — |
| P/B Ratio | 0.94 | 3.17 | 1.26 | 0.72 | 1.00 | 1.91 | 4.94 | 1.59 | 2.94 | 3.63 | 2.58 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LPCN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 20.56 | 1.81 | — | 64.87 | 5.34 | — | 44.80 | 69.95 | — | — |
| EV / EBITDA | — | — | — | — | — | 27.40 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
LPCN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lipocine Inc. earns an operating margin of -524.7%. Operating margins have compressed from 629.0% to -524.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -54.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -334.3% | -334.3% | 100.0% | 456.9% | -1611.4% | 52.5% | — | -4426.5% | 100.0% | — | — |
| Operating Margin | -524.7% | -524.7% | -10.3% | 629.0% | -2423.9% | 19.5% | — | -7818.8% | -2646.0% | — | — |
| Net Profit Margin | -487.1% | -487.1% | 0.1% | 573.6% | -2151.7% | -3.9% | — | -7883.7% | -2724.1% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -54.3% | -54.3% | 0.0% | -58.4% | -26.5% | -2.1% | -193.9% | -165.5% | -82.1% | -93.3% | -55.8% |
| ROA | -48.7% | -48.7% | 0.0% | -54.0% | -23.9% | -1.6% | -93.2% | -64.2% | -50.5% | -79.7% | -52.2% |
| ROIC | -64.7% | -64.7% | -5.7% | -55.9% | -23.5% | 10.1% | -497.9% | -126.3% | -62.0% | -87.9% | -65.2% |
| ROCE | -58.5% | -58.5% | -5.6% | -63.8% | -29.3% | 9.6% | -107.6% | -83.1% | -64.1% | -94.3% | -54.3% |
LPCN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.05 | 0.36 | 1.14 | 1.09 | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.73 | — | — | — | — | — |
| Net Debt / Equity | — | -0.36 | -0.30 | -0.23 | -0.09 | -0.01 | -0.89 | -0.41 | 0.23 | -0.17 | -0.21 |
| Net Debt / EBITDA | — | — | — | — | — | -0.20 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -396.00 | -2.12 | -46.55 | -35.66 | — | — | — |
Net cash position: cash ($5M) exceeds total debt ($0)
LPCN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lipocine Inc.'s current ratio of 6.68x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 8.69x to 6.68x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.68 | 6.68 | 14.75 | 8.69 | 20.34 | 8.26 | 3.85 | 3.95 | 4.63 | 3.97 | 20.52 |
| Quick Ratio | 6.68 | 6.68 | 14.75 | 8.69 | 20.34 | 8.26 | 3.85 | 3.95 | 4.63 | 3.97 | 20.52 |
| Cash Ratio | 5.91 | 5.91 | 14.30 | 8.37 | 19.38 | 7.94 | 2.99 | 2.83 | 3.40 | 3.38 | 20.24 |
| Asset Turnover | — | 0.12 | 0.50 | -0.12 | 0.01 | 0.31 | — | 0.01 | 0.02 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 2.62 | 3.93 | -6.69 | 481.69 | 5.59 | — | 36.55 | 32.84 | — | — |
LPCN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lipocine Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $6M | $5M | $5M | $5M | $5M | $3M | $2M | $1M | $1M | $1M |
Peer Comparison
Compare LPCN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LPCNYou | $13M | -1.4 | — | — | -334.3% | -524.7% | -54.3% | -64.7% | — |
 ANIP | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 TLSA | $192M | -6.9 | — | — | — | — | -250.5% | -481.7% | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 CLDX | $2B | -8.5 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 MNKD | $1B | 177.5 | 29.3 | 80.1 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 CLRB | $14M | -0.4 | — | — | — | — | -180.0% | — | — |
 IQV | $30B | 22.8 | 13.0 | 14.8 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See LPCN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LPCN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LPCN vs ANIP
Side-by-side business, growth, and profitability comparison vs ANI Pharmaceuticals, Inc..
Start ComparisonLPCN — Frequently Asked Questions
Quick answers to the most common questions about buying LPCN stock.
What is Lipocine Inc.'s P/E ratio?
Lipocine Inc.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
What is Lipocine Inc.'s ROE?
Lipocine Inc.'s return on equity (ROE) is -54.3%. The historical average is -65.0%.
Is LPCN stock overvalued?
Based on historical data, Lipocine Inc. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Lipocine Inc.'s profit margins?
Lipocine Inc. has -334.3% gross margin and -524.7% operating margin.